Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Research and Development, Kyowa Kirin Co Ltd, Tokyo, Japan; and.
Blood. 2021 Dec 16;138(24):2555-2569. doi: 10.1182/blood.2021011576.
Neutrophils play an essential role in innate immune responses to bacterial and fungal infections, and loss of neutrophil function can increase the risk of acquiring lethal infections in clinical settings. Here, we show that engineered neutrophil-primed progenitors derived from human induced pluripotent stem cells can produce functional neutrophil-like cells at a clinically applicable scale that can act rapidly in vivo against lethal bacterial infections. Using 5 different mouse models, we systematically demonstrated that these neutrophil-like cells migrate to sites of inflammation and infection and increase survival against bacterial infection. In addition, we found that these human neutrophil-like cells can recruit murine immune cells. This system potentially provides a straight-forward solution for patients with neutrophil deficiency: an off-the-shelf neutrophil transfusion. This platform should facilitate the administration of human neutrophils for a broad spectrum of physiological and pathological conditions.
中性粒细胞在先天免疫应答中对细菌和真菌感染起着至关重要的作用,而中性粒细胞功能的丧失会增加在临床环境中获得致命感染的风险。在这里,我们表明,源自人类诱导多能干细胞的工程化中性粒细胞前体可以在临床可应用的规模上产生功能性的类中性粒细胞细胞,这些细胞可以在体内迅速对抗致命的细菌感染。使用 5 种不同的小鼠模型,我们系统地证明了这些类中性粒细胞细胞迁移到炎症和感染部位,并提高了对细菌感染的存活率。此外,我们发现这些人类类中性粒细胞细胞可以募集小鼠免疫细胞。该系统为中性粒细胞缺乏症患者提供了一种直接的解决方案:现成的中性粒细胞输注。该平台应该为广泛的生理和病理条件下的人类中性粒细胞的管理提供便利。